CD8A and neoplasm: Silenced YTHDF1 in DCs restrained lysosomal proteolysis and promoted the cross-presentation of tumor antigens, leading to promoted cross-priming of CD8 + T cells and enhanced therapeutic efficacy of anti-PD-L1.